Sarcopenia Management in Geriatric Cancer Patients

radyasyon_onkolojisi_102

Havva BEYAZa , Evrim METCALFEb
aAnkara Yıldırım Beyazıt University Faculty of Medicine, Ankara Bilkent City Hospital, Department of Radiation Oncology, Ankara, Türkiye
bİstanbul Medipol University Faculty of Medicine, Department of Radiation Oncology, İstanbul, Türkiye

Beyaz H, Metcalfe E. Sarcopenia management in geriatric cancer patients. In: Metcalfe E, ed. Radiotherapy and Current Developments in Geriatric Cancers. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.59-64.

ABSTRACT
Sarcopenia is a syndrome commonly seen in older adults, characterized by the loss of muscle mass, strength, and physical performance. The most common causes are muscle loss due to aging, malnutrition, a sedentary lifestyle, chronic diseases, and drug treatments. This syndrome is more prevalent among geriatric cancer patients, and its presence has been associated with functional impairment, increased treatment toxicity, poor prognosis, and increased mortality in cancer patients. Cancer cachexia, where weight loss and fat mass loss predominate, is also frequently seen in conjunction with sarcopenia in these patients. There are many different techniques to evaluate muscle loss in the diagnosis of sarcopenia. It is not appropriate to diagnose sarcopenia solely as a loss of muscle mass; muscle strength and physical performance should also be evaluated according to established definition criteria. A combination of nutritional intervention and physical exercise is recommended in the treatment of sarcopenia. Early diagnosis and treatment of sarcopenia is crucial, as it is a determinant of toxicity of treatment and survival in cancer patients.

Keywords: Sarcopenia; geriatrics; radiation oncology

Referanslar

  1. Rosenberg IH. Epidemiologic and methodologic problems in determining nutritional status of older persons (Summary comments). Am J Clin Nutr. 1989;50:1231-3. [Crossref]
  2. Colloca G, Di Capua B, Bellieni A, Cesari M, Marzetti E, Valentini V, et al. Muscoloskeletal aging, sarcopenia and cancer. Journal of Geriatric Oncology. 2019;10(3):504-9. [Crossref]  [PubMed]
  3. Williams GR, Chen Y, Kenzik KM, McDonald A, Shachar SS, Klepin HD, et al. Assessment of sarcopenia measures, survival, and disability in older adults before and after diagnosis with cancer. JAMA Netw Open. 2020;3(5): e204783-e204783. [Crossref]  [PubMed]  [PMC]
  4. Pahor M, Manini T, Cesari M. Sarcopenia: clinical evaluation, biological markers and other evaluation tools. JNHA-The Journal of Nutrition, Health and Aging. 2009;13:724-8. [Crossref]  [PubMed]  [PMC]
  5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and ageing. 2010;39(4):412-23. [Crossref]  [PubMed]  [PMC]
  6. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(1):16-31. [Crossref]  [PubMed]  [PMC]
  7. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Direct Ass. 2019;21(3):300-7. [Crossref]  [PubMed]
  8. Bhasin S, Travison TG, Manini TM, Patel S, Pencina KM, Fielding RA, et al. Sarcopenia definition: the position statements of the sarcopenia definition and outcomes consortium. J Am Geriat Soci. 2020;68(7):1410-8. [Crossref]  [PubMed]
  9. Kiss N, Loeliger J, Findlay M, Isenring E, Baguley BJ, Boltong A, et al. Clinical Oncology Society of Australia: position statement on cancer‐related malnutrition and sarcopenia. Nutrition & Dietetics. 2020;77(4):416-25. [Crossref]  [PubMed]  [PMC]
  10. Sakuma K,Yamaguchi A. Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. Journal of cachexia, sarcopenia and muscle. 2012;3:77-94. [Crossref]  [PubMed]  [PMC]
  11. Sun Q, Jiang X, Qin R, Yang Y, Gong Y, Wang K, et al. Sarcopenia among older patients with cancer: A scoping review of the literature. Journal of Geriatric Oncology. 2022;13(7):924-34. [Crossref]  [PubMed]
  12. Rier HN, Jager A, Meinardi MC, van Rosmalen J, Kock MC, Westerweel PE, et al. Severe sarcopenia might be associated with a decline of physical independence in older patients undergoing chemotherapeutic treatment. Supportive Care in Cancer. 2018;26:1781-9. [Crossref]  [PubMed]
  13. Pamoukdjian F, Bouillet T, Lévy V, Soussan M, Zelek L, Paillaud E. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. Clinical Nutrition. 2018;37(4);1101-13. [Crossref]  [PubMed]
  14. Fukuda Y, Yamamoto K, Hirao M, Nishikawa K, Nagatsuma Y, Nakayama T, et al. Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy. Gastric cancer. 2016;19:986-93. [Crossref]  [PubMed]
  15. Park SE, Hwang IG, Choi CH, Kang H, Kim BG, Park BK, et al. Sarcopenia is poor prognostic factor in older patients with locally advanced rectal cancer who received preoperative or postoperative chemoradiotherapy. Medicine. 2018;97(48):e13363. [Crossref]  [PubMed]  [PMC]
  16. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. European journal of cancer. 2016;57:58-67. [Crossref]  [PubMed]
  17. Buentzel J, Heinz J, Bleckmann A, Bauer C, Roever C, Bohnenberger H, et al. Sarcopenia as prognostic factor in lung cancer patients: a systematic review and meta-analysis. Anticancer research. 2019;39(9):4603-12. [Crossref]  [PubMed]
  18. Hua X, Liu S, Liao JF, Wen W, Long ZQ, Lu ZJ, et al. When the loss costs too much: a systematic review and meta-analysis of sarcopenia in head and neck cancer. Frontiers in Oncology. 2020;9:1561. [Crossref]  [PubMed]  [PMC]
  19. Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin nutr. 2017;36(1):49-64. [Crossref]  [PubMed]
  20. Peterson SJ, Mozer M. Differentiating sarcopenia and cachexia among patients with cancer. Nutrition in clinical practice. 2017;32(1):30-9. [Crossref]  [PubMed]
  21. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. LANCET. 2011;12(5):489-95. [Crossref]  [PubMed]
  22. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clinical nutrition. 2008;27(6):793-9. [Crossref]  [PubMed]
  23. Barazzoni R, Bischoff SC, Boirie Y, Busetto L, Cederholm T, Dicker D. et al. Sarcopenic obesity: Time to meet the challenge. Clin Nutr. 2018;37:1787-93. [Crossref]  [PubMed]
  24. Gortan Cappellari G, Brasacchio C, Laudisio D, Lubrano C, Pivari F, Barrea L. et al. Sarcopenic obesity: what about in the cancer setting? Nutrition. 2022;98:111624. [Crossref]  [PubMed]
  25. Jurdana M, Cemazar M. Sarcopenic obesity in cancer. Radiol Oncol. 2024;58(1):1-8. [Crossref]  [PubMed]  [PMC]
  26. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997-1006. [Crossref]  [PubMed]
  27. Colloca G, Di Capua B, Bellieni A, Cesari M, Marzetti E, Valentini V, et al. Muscoloskeletal aging, sarcopenia and cancer. J Geriatr Oncol. 2019;10(3):504-9. [Crossref]  [PubMed]
  28. Mijnarends DM, Meijers JM, Halfens RJ, ter Borg S, Luiking YC, Verlaan S, et al. Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people: a systematic review. J Am Med Dir Assoc. 2013;14(3):170-8. [Crossref]  [PubMed]
  29. Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, diagnosis and management. J Nutr Health Aging. 2018;22:1148-116. [Crossref]  [PubMed]
  30. Gewandter JS, Dale W, Magnuson A, Pandya C, Heckler CE, Lemelman T, et al. Associations between a patient-reported outcome (PRO) measure of sarcopenia and falls, functional status, and physical performance in older patients with cancer. J Geriatr Oncol. 2015;6(6):433-41. [Crossref]  [PubMed]  [PMC]
  31. Dunne RF, Loh KP, Williams GR, Jatoi A, Mustian KM, Mohile SG. Cachexia and Sarcopenia in Older Adults with Cancer: A Comprehensive Review. Cancers (Basel). 2019;11(12):1861. [Crossref]  [PubMed]  [PMC]
  32. Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326-47. [Crossref]  [PubMed]  [PMC]
  33. Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology. 2014;60(4):294-305. [Crossref]  [PubMed]  [PMC]
  34. Cruz-Jentoft AJ, Landi F, Schneider SM, Zúñiga C, Arai H, Boirie Y, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing. 2014;43(6):748-59. [Crossref]  [PubMed]  [PMC]
  35. Bear DE, Langan A, Dimidi E, Wandrag L, Harridge SDR, Hart N, et al. β-Hydroxy-βmethylbutyrate and its impact on skeletal muscle mass and physical function in clinical practice: a systematic review and meta-analysis. Am J Nutr 2019;109:1119-32. [Crossref]  [PubMed]
  36. Maykish A, Sikalidis AK. Utilization of hydroxyl-methyl butyrate, leucine, glutamine and arginine supplementation in nutritional management of sarcopenia-implication and clinical considerations for type 2 diabetes mellitus risk modulation. J. Pers. Med. 2020;10:19. [Crossref]  [PubMed]  [PMC]
  37. Holeček M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions. J Cachexia Sarcopenia Muscle. 2017;8(4):529-41. [Crossref]  [PubMed]  [PMC]
  38. Shefflette A, Patel N, Caruso J. Mitigating Sarcopenia with Diet and Exercise. Int J Environ Res Public Health. 2023;20(17):6652. [Crossref]  [PubMed]  [PMC]
  39. Kakehi S, Wakabayashi H, Inuma H, Inose T, Shioya M, Aoyama Y, et al. Rehabilitation nutrition and exercise therapy for sarcopenia. World J. Mens Health. 2022;40:1-10. [Crossref]  [PubMed]  [PMC]
  40. Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519-31. [Crossref]  [PubMed]
  41. de Spiegeleer A, Beckwe D, Bautmans I, Petrovic M. Sarcopenia Guidelines Development Group for the Belgian Society of Gerontology and Geriatrics (BSGG). Pharmacological interventions to improve muscle mass, muscle strength and physical performance in older people: an umbrella review of systematic reviews and metaanalyses. Drugs Aging. 2018;35:719-34. [Crossref]  [PubMed]
  42. Landi F, Marzetti E, Martone AM, Bernabei R, Onder G. Exercise as a remedy for sarcopenia. Curr Opin Clin Nutr Metab Care. 2014;17(1):25-31. [Crossref]  [PubMed]
  43. Fragala MS, Cadore EL, Dorgo S, Izquierdo M, Kraemer WJ, Peterson MD, et al. Resistance Training for Older Adults. J. Strength Cond. Res. 2019;33:2019-52. [Crossref]  [PubMed]
  44. Hurst C, Robinson SM, Witham MD, Dodds RM, Granic A, Buckland C, et al. Resistance exercise as a treatment for sarcopenia: Prescription and delivery. Age Ageing. 2022;51:afac003. [Crossref]  [PubMed]  [PMC]
  45. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: A randomized controlled trial. J. Clin. Oncol. 2010;28:340-7. [Crossref]  [PubMed]
  46. Adams SC, Segal RJ, McKenzie DC, Vallerand JR, Morielli AR, Mackey JR, et al. Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: A multicenter randomized controlled trial. Breast Cancer Res. Treat. 2016;158:497-507. [Crossref]  [PubMed]
  47. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med. Sci. Sports Exerc. 2010;42:1409-26. [Crossref]  [PubMed]